Get in Touch with a Diabetes Consultant
Download Guide for Your Appointment
An insulin pump is a small device that can help you manage your diabetes. It delivers continuous and customized doses of rapid-acting insulin 24 hours a day to match your body’s needs. The pump provides insulin to your body in two ways:
A pump delivers insulin to the body through a thin, flexible tube called an infusion set.
People can experience many positive changes in their life when switching to pump therapy.
With an insulin pump, you’ll only need to insert an infusion set every few days. When using multiple daily injections, people often take shots several times a day. Multiple daily injections defined as 3 or more shots a day.
The bolus calculator eliminates complex math and tracks active insulin. Tracking active insulin can help avoid stacking and going low
May help you achieve better glucose control with fewer highs and lows†
Ask your healthcare professional about insulin pump therapy if you:
There are many ways a pump can be worn. It can be comfortably worn during work, exercise, formal occasions and everyday life. Hover over the images below to see how others wear their pump.
When it comes to your diabetes management, cost should not prevent you from accessing advanced diabetes technology. Our team will work with you to help ensure that you can experience the benefits of insulin pump therapy.
PRIVATE INSURANCE‡
Most private insurance companies cover insulin pumps under the durable medical equipment portion of your policy. Depending on your insurance coverage, you might have to pay a deductible and/or percent of the cost (co-insurance). If your deductible and out-of-pocket maximum has been met, the insulin pump might be covered at 100% by your insurance.
GOVERNMENT INSURANCE‡
Government insurances such as Medicare and Medicaid may cover insulin pumps depending on the state and other requirements. A patient's out-of-pocket cost under government insurance varies depending on the policy.
INSURANCE PROCESSING
When you start the process of getting an insulin pump, you do not have to worry about the paperwork. Medtronic will help you every step of the way by verifying your insurance, providing an estimated out-of-pocket cost, collecting the documents from you and your physician, and submitting all the required documents to your insurance company.
PAYMENT OPTIONS
If you do not have insurance or need assistance with your out-of-pocket cost, Medtronic offers flexible payment options and a financial assistance program for qualifying customers.
Medtronic insulin pumps are covered by most insurance plans. To request a free insurance coverage check and learn more about your eligibility and potential out-of-pocket costs please complete the form below or call 1-888-350-5440 and one of our Diabetes Therapy consultants will be happy to assist you.
The MiniMed™ 770G insulin pump system automatically adjusts background insulin every 5 minutes.† Using real-time glucose readings, the system is able to calculate a personalized amount of insulin to deliver based on your needs. The system connects directly with a smartphone, allowing you to easily view sugar levels and insulin delivery history.
The MiniMed™ 630G insulin pump delivers precise doses of insulin to your body. When combined with our CGM, it takes action for you with the SmartGuard™ Suspend on low feature - providing protection that can help keep your glucose levels stable.∆ ,3
* At the time of manufacture and when the reservoir and tubing are properly inserted, your pump is waterproof. It is protected against the effects of being underwater to a depth of up to 12 feet (3.6 meters) for up to 24 hours. This is classified as IPX8 rating. See user guide for more details. The sensor and transmitter are water-resistant at 8 feet (2.4 meters) for up to 30 minutes. CGM readings may not be transmitted from the CGM to the pump while in water.
† Refers to SmartGuard™ Auto Mode. Some interaction required. Individual results may vary.
∆ WARNING: Do not use the Suspend on low feature to prevent or treat low glucose. Always confirm your sensor glucose reading using your BG meter, and follow the instructions of your healthcare professional to treat low glucose. Using Suspend on low alone to prevent or treat low glucose may result in prolonged hypoglycemia.
‡ Coverage guidelines for insulin pumps vary and are subject to the insurance companies published medical policies in effect at the time services are requested.
Φ Arm indication approved for ages 14-75.
1. Heinemann L, Weyer C, Rauhaus M, Heinrichs S, Heise T. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin anolog insulin aspart.Diabetes Care.1998;21:1910-1914.
2. Heise T, Nosek L, Ronn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53:1614-1620.
3. Bergenstal RM,Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363:311–320.
Individuals pictured and/or quoted here were compensated for spending the day with us and allowing us to photograph them and their family. Their thoughts and opinions are their own.
Important Safety Information: MiniMed™ 770G System With SmartGuard™ Technology
The MiniMed™ 770G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons two years of age and older requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 770G System includes SmartGuard™ technology, which can be programmed to automatically adjust delivery of basal insulin based on continuous glucose monitoring (CGM) sensor glucose values (SG) and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values.
The Medtronic MiniMed™ 770G System consists of the following devices: MiniMed™ 770G Insulin Pump, the Guardian™ Link (3) Transmitter, the Guardian™ Sensor (3), one-press serter, the Accu-Chek® Guide Link blood glucose meter, and the AccuChek®Guide Test Strips. The system requires a prescription.
The Guardian™ Sensor (3) has not been evaluated and is not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. All therapy adjustments should be based on measurements obtained using a blood glucose meter and not on values provided by the Guardian™ Sensor (3).
All therapy adjustments should be based on measurements obtained using the Accu-Chek® Guide Link blood glucose meter and not on values provided by the Guardian™ Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the Accu-Chek® Guide Link blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an alternative site. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise.
WARNING: Do not use the SmartGuard™ Auto Mode for people who require less than 8 units or more than 250 units of total daily insulin per day. A total daily dose of at least 8 units, but no more than 250 units, is required to operate in SmartGuard™ Auto Mode.
WARNING: Do not use the MiniMed™ 770G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed™ 770G system.
Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed™ 770G system has not been studied in pregnant women. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult https://www.medtronicdiabetes.com/important-safetyinformation#minimed-770g and the appropriate user guide at https://www.medtronicdiabetes.com/download-library
Important Safety Information: MiniMed™ 670G System
The Medtronic MiniMed™ 670G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons, seven years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 670G system includes SmartGuard™ technology, which can be programmed to automatically adjust delivery of basal insulin based on Continuous Glucose Monitor sensor glucose values, and can suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values. The system requires a prescription. The Guardian™ Sensor (3) glucose values are not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. A confirmatory finger stick test via the CONTOUR®NEXT LINK 2.4 blood glucose meter is required prior to making adjustments to diabetes therapy. All therapy adjustments should be based on measurements obtained using the CONTOUR®NEXT LINK 2.4 blood glucose meter and not on values provided by the Guardian™ Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the CONTOUR®NEXT LINK 2.4 blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an Alternative Site (palm) or from a control solution test. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always” send mode.
WARNING: Medtronic performed an evaluation of the MiniMed™ 670G system and determined that it may not be safe for use in children under the age of 7 because of the way that the system is designed and the daily insulin requirements. Therefore this device should not be used in anyone under the age of 7 years old. This device should also not be used in patients who require less than a total daily insulin dose of 8 units per day because the device requires a minimum of 8 units per day to operate safely.
Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed™ 670G system has not been studied in pregnant women. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult http://www.medtronicdiabetes.com/important-safety-information#minimed-670g and the appropriate user guide at http://www.medtronicdiabetes.com/download-library.
Important Safety Information: MiniMed™ 630G System
Indicated for the continuous delivery of insulin, at set and variable rates, for the management of diabetes mellitus. MiniMed™ 630G system is approved for ages 14 years or older with Guardian™ Sensor 3 and MiniMed™ 630G system is approved for ages 16 years or older with Enlite™ sensor. Both systems require a prescription. Insulin infusion pumps and associated components of insulin infusion systems are limited to sale by or on the order of a physician and should only be used under the direction of a healthcare professional familiar with the risks of insulin pump therapy. Pump therapy is not recommended for people who are unwilling or unable to perform a minimum of four blood glucose tests per day. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Insulin pumps use rapid-acting insulin. If your insulin delivery is interrupted for any reason, you must be prepared to replace the missed insulin immediately. Replace the infusion set every 48–72 hours, or more frequently per your healthcare professional’s instructions. Insertion of a glucose sensor may cause bleeding or irritation at the insertion site. Consult a physician immediately if you experience significant pain or if you suspect that the site is infected. The information provided by CGM systems is intended to supplement, not replace, blood glucose information obtained using a blood glucose meter. A confirmatory fingerstick using a CONTOUR®NEXT LINK 2.4 meter is required prior to making adjustments to diabetes therapy. Always check the pump display when using a CONTOUR®NEXT LINK 2.4 meter, to ensure the glucose result shown agrees with the glucose results shown on the meter. Do not calibrate your CGM device or calculate a bolus using a result taken from an Alternative Site (palm) or a result from a control solution test. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always” send mode. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. The MiniMed™ 630G system is not intended to be used directly for preventing or treating hypoglycemia but to suspend insulin delivery when the user is unable to respond to the Suspend on low alarm and take measures to prevent or treat hypoglycemia themselves. Therapy to prevent or treat hypoglycemia should be administered according to the recommendations of the user’s healthcare provider.
WARNING: The SmartGuard™ Suspend on low feature will cause the pump to temporarily suspend insulin delivery for two hours when the sensor glucose reaches a set threshold. Under some conditions of use the pump can suspend again, resulting in very limited insulin delivery. Prolonged suspension can increase the risk of serious hyperglycemia, ketosis, and ketoacidosis. Before using the SmartGuard feature, it is important to read the SmartGuard™ feature information in the User Guide and discuss proper use of the feature with your healthcare provider.
See important safety information and the appropriate user guides for additional important details.
Ascensia, the Ascensia Diabetes Care logo, and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care.